Eastern Mediterranean (WHO region) vs Montenegro: Treatment success rate for patients treated for MDR-TB
Eastern Mediterranean (WHO region)
75.0%
in 2022
Montenegro
100.0%
in 2018
Eastern Mediterranean (WHO region) rank
4th
Montenegro rank
1st
Treatment success rate for patients treated for MDR-TB over time
- Eastern Mediterranean (WHO region)
- Montenegro
How they compare
Montenegro currently reports 100.0% against 75.0% in Eastern Mediterranean (WHO region), a difference of 25.0%.
That makes Montenegro's figure about 1.3 times Eastern Mediterranean (WHO region)'s.
The two have swapped places 6 times across 8 shared years of data; in 2006 it was Montenegro ahead.
Eastern Mediterranean (WHO region) ranks 4th and Montenegro ranks 1st of 11 groups.
Across the 2 decades both report, Eastern Mediterranean (WHO region) averaged higher in 1 and Montenegro in 1.
Head to head by decade
| Decade | Eastern Mediterranean (WHO region) | Montenegro | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 46.3% | 55.7% | 9.3% | Montenegro |
| 2010s | 65.0% | 60.0% | 5.0% | Eastern Mediterranean (WHO region) |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher treatment success rate for patients treated for mdr-tb, Eastern Mediterranean (WHO region) or Montenegro?
- Montenegro, at 100.0% against 75.0% in Eastern Mediterranean (WHO region) as of 2018.
- What is the difference in treatment success rate for patients treated for mdr-tb between Eastern Mediterranean (WHO region) and Montenegro?
- 25.0%, with Montenegro ahead.
- How many years of comparable data are there for Eastern Mediterranean (WHO region) and Montenegro?
- 8 years are reported by both, from 2006 to 2018.
- How do Eastern Mediterranean (WHO region) and Montenegro rank globally for treatment success rate for patients treated for mdr-tb?
- Eastern Mediterranean (WHO region) ranks 4th and Montenegro ranks 1st of 11 groups.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Treatment success rate for patients treated for MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.